Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 2/20 | 0.54 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.54 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.54 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.53 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.53 |
| ▸ | ALPI | P09923 | 1/20 | 0.53 |
| ▸ | XIAP | P98170 | 1/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1663153 | 1.00 | SLC1A3 (0.54) | SLC1A3SLC1A2SLC1A1SLC7A5PKM | |
| SCHEMBL599915 | 1.00 | SLC1A3 (0.54) | SLC1A3SLC1A2SLC1A1SLC7A5PKM | |
| Trifluoroacetic Acid SCHEMBL4806415 | 0.91 | GRB2 (0.50) | SLC1A3SLC1A2SLC1A1SLC7A5PKM | |
| D-Glutamate SCHEMBL29008193 | 0.87 | SLC1A3 (0.50) | SLC1A3SLC1A2SLC1A1SLC7A5PKM | |
| SCHEMBL6248383 | 0.85 | ALOX5 (0.54) | SLC1A3SLC1A2SLC1A1ALOX5POLB | |
| SCHEMBL6248378 | 0.85 | ALOX5 (0.54) | SLC1A3SLC1A2SLC1A1ALOX5POLB | |
| SCHEMBL10305129 | 0.85 | ALOX5 (0.54) | SLC1A3SLC1A2SLC1A1ALOX5POLB | |
| SCHEMBL2265386 | 0.85 | SLC1A1 (0.59) | SLC1A3SLC1A2SLC1A1ALOX5 | |
| SCHEMBL9554473 | 0.84 | SLC7A5 (0.46) | SLC1A3SLC1A2SLC1A1SLC7A5PKM | |
| SCHEMBL12240912 | 0.84 | ALDH1A1 (0.50) | SLC1A3SLC1A2SLC1A1SLC7A5PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 825 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025119908-A1 | PSMA-TARGETING FLUORESCENT PROBES | BRACCO IMAGING SPA (IT) | 2025-06-12 | — | — | WO | claimed |
| US-11512114-B2 | Modified microcystins and nodularins | CYANO BIOTECH GMBH (DE) | 2022-11-29 | — | — | US | claimed |
| CN-113788877-A | Novel insect kinin analogs and application thereof in aphid control | 中国农业大学 | 2021-12-14 | — | — | CN | claimed |
| US-11124818-B2 | Method for modifying microcystins and nodularins | CYANO BIOTECH GMBH (DE) | 2021-09-21 | — | — | US | claimed |
| CN-113045625-A | Polypeptide as growth hormone secretagogue receptor agonist and application thereof | 成都诺和晟泰生物科技有限公司 | 2021-06-29 | — | — | CN | claimed |
| US-20200377922-A1 | METHOD FOR MODIFYING MICROCYSTINS AND NODULARINS | CYANO BIOTECH GMBH (DE) | 2020-12-03 | — | — | US | claimed |
| US-20200247858-A1 | AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF | FOG PHARMACEUTICALS, INC. (US) | 2020-08-06 | — | — | US | claimed |
| EP-3678683-A2 | AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF | Fog Pharmaceuticals, Inc. (US) | 2020-07-15 | — | — | EP | claimed |
| US-20200087348-A1 | MODIFIED MICROCYSTINS AND NODULARINS | CYANO BIOTECH GMBH (DE) | 2020-03-19 | — | — | US | claimed |
| US-20190177370-A1 | PEPTIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, OR PRODRUG THEREOF | TOKYO UNIVERSITY OF PHARMACY & LIFE SCIENCES (JP) | 2019-06-13 | — | — | US | claimed |
| EP-0636146-A1 | TACHYKININ ANTAGONIST TRICYCLIC COMPOUNDS, PREPARATION OF SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS. | MENARINI FARMA IND (IT) | 1995-02-01 | — | — | EP | claimed |
| EP-0276014-B1 | Anticoagulant peptides | MERRELL DOW PHARMA (US) | 1994-08-31 | — | — | EP | claimed |
| EP-0370454-B1 | Renin-inhibiting amino diol derivatives | HOECHST AG (DE) | 1994-04-20 | — | — | EP | claimed |
| EP-0255082-B1 | Renin-inhibiting di- and tripeptides, methods for their production, drugs containing them, and their use | HOECHST AG (DE) | 1993-12-01 | — | — | EP | claimed |
| WO-1993021227-A1 | TACHYKININ ANTAGONIST TRICYCLIC COMPOUNDS, PREPARATION OF SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS | A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE S.R.L. (IT) | 1993-10-28 | — | — | WO | claimed |
| EP-0373549-B1 | AMINO ACID DERIVATIVES WITH ENZYME-INHIBITING PROPERTIES, PROCESS TO SYNTHETISE THEM, COMPOSITION CONTAINING THEM AND THEIR USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-09-01 | — | — | EP | claimed |
| US-5204357-A | RENIN-INHIBITING AMINO ACID DERIVATIVES | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-04-20 | — | — | US | claimed |
| EP-0394829-A1 | Renin-inhibiting dipeptides, process to synthetize them, compositions containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-10-31 | — | — | EP | claimed |
| US-4855286-A | HYPOTENSIVE AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-08-08 | — | — | US | claimed |
| US-4407952-A | OF GENETICALLY ENGINEERED ESCHERICHIA | AJINOMOTO COMPANY INCORPORATED (JP) | 1983-10-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177370-A1 | PEPTIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, OR PRODRUG THEREOF | MYOF, MSTN, VIP | SLC1A3 401/4885SLC1A2 683/4885SLC1A1 447/4885 |
| US-20200247858-A1 | AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF | CTNNB1, CTNNBL1, CTNNA1 | SLC1A3 4776/4885SLC1A2 4802/4885SLC1A1 4795/4885 |
| US-11124818-B2 | Method for modifying microcystins and nodularins | NRDC, NGLY1, NLN | SLC1A3 988/4885SLC1A2 1917/4885SLC1A1 1641/4885 |
| US-20200377922-A1 | METHOD FOR MODIFYING MICROCYSTINS AND NODULARINS | NRDC, NGLY1, NLN | SLC1A3 842/4885SLC1A2 1688/4885SLC1A1 1445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.